

APPLICATION GUIDE

TruePLEX™ Antibody Profiling Array: Human Pancreatic Cancer IV

Part Number: AP1000017

For multiplex detection of human antibodies to the following proteins with the Luminex xMAP® system.

Gene Symbol	Name
HERPUD1	Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1
HCFC1R1	Host cell factor C1 regulator 1 (XPO1 dependent)
PPARG	Peroxisome proliferator-activated receptor gamma
ROR2	Receptor tyrosine kinase-like orphan receptor 2
RNF213 (KIAA1618)	Ring finger protein 213

For use in conjunction with the TruePLEX™ Human Antibody Profiling Kit
Part Number: AP100001

For Research Use Only

TABLE OF CONTENTS

Ordering Information	3
Custom Profiling Arrays	3
Storage Instructions	3
Overview and Intended Use	4
Assay Principles	4
Protein Source and characterization	4
Important Information	5
Recombinant Proteins	6
Assay Protocol	6
Creating larger multiplexes with additional Protein Bead Arrays	6
Troubleshooting	6
References	6

Ordering Information

TruePlex™ Human Antibody Profiling Kit (96 tests)

Catalog #: AP100001

TruePlex™ Antibody Profiling Arrays for pancreatic cancer:

Human Pancreatic Cancer I 5-plex (96 tests) Catalog # AP1000014	ULK4, MAPK9, NR2E3, PGK1, PTPRA
Human Pancreatic Cancer II 5-plex (96 tests) Catalog # AP100015	IDH1, MDH1, G6PD, ALDH1A1, SMOX
Human Pancreatic Cancer III 5-plex (96 tests) Catalog # AP100016	CTDSP1, ELAC1, CD79B, DNAJB1, GAS2
Human Pancreatic Cancer IV 5-plex (96 tests) Catalog # AP100017	HERPUD1, HCFC1R1, PPARG, ROR2, RNF213 (KIAA1618)
Human Pancreatic Cancer V 5-plex (96 tests) Catalog # AP100018	SHOC2, TMSB10, TMOD1, PDLIM1, PGK1
Human Pancreatic Cancer IV 5-plex (96 tests) Catalog # AP100019	ARFIP2, CFL1, TAGLN2, TPI1, EIF4A3 (DDX48)

Additional panels are available for breast, prostate, lung, and ovarian cancer as well as for many autoimmune antigens. (see:

<http://www.origene.com/Luminex/Proteinarray.aspx>)

Multiple profiling arrays can be mixed together and analyzed as a larger multiplex.

Custom Profiling Arrays

Custom profiling arrays comprising beads coupled to any of OriGene's 8400+ recombinant proteins are available. Please send an inquiry to assays@origene.com.

Storage Instructions

- Store the vial of bead mix at -20°C.

Overview and Intended Use

Human autoantibodies are known to play a pivotal role in many diseases including over 170 human autoimmune diseases and many cancers. Many autoantibody antigens have been identified, but others remain elusive or difficult to confirm. In addition, many questions remain unanswered regarding the role of autoantibodies in the pathology and natural history of the disease. OriGene has purified over 8000 recombinant human proteins from human cells that can be used for autoantibody testing. This kit is intended to be used as a basic research tool for the detection of human autoimmune antibodies in serum and plasma for basic and clinical research studies. It is not intended for use in clinical diagnostics.

Assay Principles

Recombinant human proteins have been expressed and purified from a human cell line (HEK-293T). Purified recombinant proteins have been coupled to Luminex beads. Each protein is coupled to a different type or “color” of Luminex beads. A bead mix is prepared by combining all of the beads along with a set of control beads that are supplied with the detection kit. Diluted serum or plasma is mixed with the beads and autoantibodies, if present, will bind to the specific protein-coupled beads. After washing, an anti-human-phycoerythrin conjugate is added to detect the bound human IgG. After a final wash, the samples are read in the Luminex 100 or Luminex 200 instrument. The median fluorescent intensity measured for each bead reflects the amount of human IgG bound to the bead.

Protein Source and characterization

The recombinant proteins coupled to the Luminex beads have been expressed in human HEK-293 cells. Therefore, serum or plasma samples may react differently to these proteins than those expressed in *E. coli* or insect cells due to potential conformational differences and the presence of post-translational modifications on the proteins expressed in human cells.

The recombinant proteins are expressed with a fusion tag on the C-terminus:

Protein - TRTRPLEQKLISEEDLAANDILDYKDDDDKV

The sequence **EQKLISEEDL** is known as the myc tag.

The sequence **DYKDDDDK** is known as the DDK or FLAG™ tag.

The tag provides for efficient purification of the recombinant proteins from the HEK-293 cells and allows for verification that sufficient protein has been coupled to the beads. The tag sequence also serves as a positive control for the assay performance.

Important Information

- **Research Use Only.** The product you have received is authorized for laboratory research use only. The product has not been qualified or found safe and effective for any human or animal diagnostic or therapeutic application. Uses other than the labeled intended use may be a violation of applicable law.
- **Hazards.** It is the end-user's responsibility to consult the applicable MSDS(s) before using this product. Disposal of waste materials must comply with all appropriate federal, state, and local regulations. If you have any questions concerning the hazards associated with this product, please call OriGene Technologies Inc at 1-888-267-4436.
- **Terms and Conditions:** By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the following terms and conditions. You are also agreeing that the following terms and conditions constitute a legally valid and binding contract that is enforceable against you. If you do not agree to all of the terms and conditions set forth below, you must promptly return this Assay Product for a full refund prior to using it in any manner. You, the customer, acquire the right under Luminex Corporation's patent rights, if any, to use this Assay Product or any portion of this Assay Product, including without limitation the microsphere beads contained herein, only with Luminex Corporation's laser based fluorescent analytical test instrumentation marketed under the name Luminex Instrument.
- **Safety and Use:** All biological materials should be handled as potentially hazardous. Follow universal precautions as established by the Centers for Disease Control and Prevention and by the Occupational Safety and Health Administration when handling and disposing of potentially infectious or hazardous agents. This product is authorized for laboratory research use only. The product has not been qualified or found safe and effective for any human or animal diagnostic application. Uses other than the labeled intended use may be a violation of applicable law.

Recombinant Proteins

Each recombinant protein is coupled to a different Luminex bead. Bead assignments can be customized.

Gene Symbol	Name	OriGene Protein SKU
HERPUD1	Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1	TP300693
HCFC1R1	Host cell factor C1 regulator 1 (XPO1 dependent)	TP309047
PPARG	Peroxisome proliferator-activated receptor gamma	TP301538
ROR2	Receptor tyrosine kinase-like orphan receptor 2	TP312502
RNF213 (KIAA1618)	Ring finger protein 213	TP312181

Additional pancreatic cancer markers are available. Contact OriGene for a complete list. (assays@origene.com).

Assay Protocol

Refer to the protocol in the TruePLEX™ Human Autoantibody Profiling Kit

Creating larger multiplexes with additional Protein Bead Arrays

Additional protein-coupled bead mixes are available and may be combined to create larger multiplexes. Custom beads arrays can also be ordered utilizing any of OriGenes over 8000+ human-expressed purified proteins. Send an inquiry to assays@origene.com for more information.

Troubleshooting

Refer to the application guide for the TruePLEX™ Human Autoantibody Detection Kit.

References

Bracci PM, Zhou M, Young S, Wiemels J. *Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study*. Cancer. 2012 Nov 1;118(21):5384-94.

Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen YT, Andrews C, Ritter G, Old LJ, Odunsi K, Jäger D. *Seromic*

profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5088-93.

Heller A, Zörnig I, Müller T, Giorgadze K, Frei C, Giese T, Bergmann F, Schmidt J, Werner J, Buchler MW, Jaeger D, Giese NA. *Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer*. Cancer Immunol Immunother. 2010 Sep;59(9):1389-400.

Hong SH. *Identification of CLP36 as a tumor antigen that induces an antibody response in pancreatic cancer*. Cancer Res Treat. 2005 Feb;37(1):71-7.

Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. *Early diagnosis of pancreatic cancer: challenges and new developments*. Biomark Med. 2012 Oct;6(5):597-612.

Li C, Kim HY, Vuong H, Patwa T, Pal M, Brand RE, Simeone DM, Lubman DM. *The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line*. Cancer Biomark. 2010;7(1):25-37.

Li J, Wang LJ, Ying X, Han SX, Bai E, Zhang Y, Zhu Q. *Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer*. Scand J Immunol. 2012 Mar;75(3):342-9.

Patwa TH, Li C, Poisson LM, Kim HY, Pal M, Ghosh D, Simeone DM, Lubman DM. *The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray*. Electrophoresis. 2009 Jun;30(12):2215-26.

Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De Angelis C, Gaia E, Salacone P, Milella M, Nisticò P, Alessio M, Chiarle R, Giuffrida MG, Giovarelli M, Novelli F. *Autoantibody signature in human ductal pancreatic adenocarcinoma*. J Proteome Res. 2007 Oct;6(10):4025-31.

Xia Q, Kong XT, Zhang GA, Hou XJ, Qiang H, Zhong RQ. *Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer*. Biochem Biophys Res Commun. 2005 May 6;330(2):526-32.